Blood compatibility evaluations of CaCO₃particles

Area of Science:

• Biomaterials Science
• Nanomedicine
• Hemocompatibility Studies

Background:

• Calcium carbonate (CaCO3) particles are utilized as carriers for bioactive molecules due to their unique properties.
• Intravenous administration of CaCO3 particles necessitates understanding their interaction with blood components.
• Lack of hemocompatibility data hinders clinical translation of CaCO3-based delivery systems.

Purpose of the Study:

• To evaluate the in vitro and in vivo hemocompatibility of CaCO3 particles.
• To investigate the effects of CaCO3 particles on red blood cells, platelets, and coagulation.
• To provide essential biosafety information for clinical applications of CaCO3 particles.

Main Methods:

• In vitro assessment of CaCO3 particle interactions with red blood cells and platelets.
• In vitro coagulation assays to evaluate effects on blood clotting.
• In vivo studies in animal models to assess systemic effects of intravenously administered CaCO3 particles.
• Histopathological examination of major organs following CaCO3 particle administration.

Main Results:

• In vitro studies showed CaCO3 particles induced red blood cell aggregation, hemolysis, platelet activation, and prolonged coagulation at high concentrations.
• In vivo administration of CaCO3 particles at 50 mg/kg significantly altered red blood cell and platelet counts.
• No significant abnormalities were observed in the tissue structures of key organs in vivo.
• A concentration of 0.1 mg/mL CaCO3 particles exhibited excellent hemocompatibility.

Conclusions:

• CaCO3 particle-induced hemotoxicity is concentration-dependent, potentially linked to their high adsorption capacity.
• The findings provide critical biosafety data for the clinical use of CaCO3 particles in drug delivery.
• CaCO3 particles at 0.1 mg/mL are suitable for in vivo biomedical applications, promoting their clinical translation.